El interés en corto de IGM Biosciences da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de IGM Biosciences. Los datos de interés en corto se actualizan cada dos semanas.

IGM Biosciences (NASDAQ:IGMS) Bolsa, Informe de interés en corto

IGM Biosciences

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

IGM Biosciences Inc

Pratt &amp; Whitney, an RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) business, has been awarded a contract valued up to $1.3 billion to continue work on the F135 Engine Core Upgrade (ECU), which will deliver enhanced durability to the engine. The ECU also provides power and cooling for Block 4 and beyond capabilities for all three variants of the F-35 global enterprise.

News

Reported Earlier, Pratt & Whitney Secures $1.3B Contract for F-35 Engine Upgrade

OBSIDIAN ENERGY LTD. (TSX:&nbsp;OBE) (NYSE:<a href="https://www.benzinga.com/stock/OBE#NYSE">OBE</a>) ("Obsidian Energy", the "Company", "we", "us" or "our") is pleased to provide an update to our 2024 guidance that includes ongoing strong second half 2024 drilling results that continue to exceed our initial expectations. As a result, we have further increased our 2024 production guidance range to 37,000 to 37,400 boe/d (midpoint of 37,200 boe/d) with associated adjustments to our funds flow from operations ("FFO") and free cash flow ("FCF").
Considering the recent softness in commodity prices and market uncertainty due to global factors, Obsidian Energy has also revised our 2024 capital expenditures downwards by approximately $15 million, reallocating a portion of light oil spending towards incremental share buybacks through our normal course issuer bid ("NCIB") and further debt reduction. In total, the reallocation of capital is only expected to impact average 2024 production by approximately 40 boe/d.
"The continued outperformance of our development program has led to a further increase to our 2024 production guidance," said Stephen Loukas, Obsidian Energy's President and CEO. "However, the recent volatility in both the broader oil and gas markets as well as with our share price has resulted in a dynamic whereby our equity valuation is significantly below new development economics within our light oil portfolio. Accordingly, Obsidian Energy's Board of Directors has approved the postponement of our fourth quarter light oil program (excluding the drilling of our initial delineation well targeting the Belly River formation in our Willesden Green area) and capital reallocation into a combination of incremental share buybacks and additional debt repayment. Notwithstanding a minor impact to 2024 production, we believe that this decision will result in superior FFO and FCF per share metrics. Moreover, it will afford Obsidian Energy's shareholders greater exposure to our growing Peace River play, preserving light oil inventory for more favourable market while still meeting our 50,000 boe/d 2026 production target."
REVISED 2024 GUIDANCE
We have revised our 2024 guidance with annual production expected to be between 37,000 to 37,400 boe/d with a midpoint of 37,200 boe/d - a 15 percent increase from 32,275 boe/d in 2023 - and an approximate $15 million decrease to capital expenditures that will be reallocated to further share buybacks and debt reduction. Although we have lowered our WTI forecast to US$72.50/bbl for the remainder of 2024, our FFO increased by $5 million to $420 million, resulting in a 2024 net debt to FFO of approximately 0.9 times and a related increase to FCF by approximately $17 million to $69 million. Our revised 2024 guidance, incorporating key assumptions used by the Company, is as follows:

Guidance

Reported Earlier, Obsidian Energy Increases 2024 Production Guidance by 15%, Cuts Capital Spending by $15M, Adjusts Capital for Share Buybacks

Vice Presidential candidates from either side of the aisle, Sen. J.D. Vance (R-Ohio) and Minnesota Governor Tim Walz will <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41107455/walz-vs-vance-vp-debate-betting-odds-what-candidate-is-favored-plus-how-to-watch-likely-to">take on each other in a debate to be televised live on CBS News on Tuesday, </a>and former President Donald Trump&#8216;s niece Mary Trump weighed in on the event in her substack post.
Media Apathy: CBS, owned by Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>), said it would not fact-check the debate in real-time but would do it in its live blog and on socials as well as in its post-debate coverage, said Mary Trump in the post published on Monday. The presidential debate between Donald Trump and Vice President Kamala Harris, hosted by ABC News, had real-time fact-checking.
The statement from CBS that moderators Margaret Brennan and Norah O'Donnell &#8220;will facilitate&#8221; opportunities for Vance and Walz to confront each other sounded like &#8220;on one hand CBS wants a food fight and, on the other, as if its comfortable giving a huge advantage to the one debate participant—Vance—who is known, like his running mate, for being an inveterate liar,&#8221; Mary Trump said.
The psychologist also said if the media doesn&#8217;t take up the onus of fact-checking information, it is incumbent on the public to spot a lie when they hear or read one.
See Also: <a href="https://www.benzinga.com/news/24/08/40278004/vance-vs-walz-how-do-trump-and-kamala-harris-vice-president-picks-net-worth-compare">Vance Vs. Walz: Comparing Net Worth Of Trump And Kamala Harris&#8217; VP Picks</a>
Violence In The Cards: If Donald Trump is elected again, there will be blood, given he has long been targeting vulnerable communities and setting them up if he loses the election,<a href="https://www.marytrump.org/p/irony-diesagain"> said</a> Mary Trump in a separate post. &#8220;The more desperate he becomes, the more openly Donald fantasizes about violence being unleashed on his behalf,&#8221; she said.
Mary Trump noted that last weekend in Pennsylvania Donald Trump lied about shoplifting and proposed &#8220;one real rough nasty day&#8221; to let police do whatever they want to alleged perpetrators.&nbsp;
&#8220;This isn't fiction and what Donald is calling for has an historical precedent,&#8221; she added. 
&#8220;Donald is clearly signaling to his extremist followers that he will not only condone but will actively welcome such episodes of violence and intimidation here,&#8221; Mary Trump said. He has stated clearly on several occasions that he wants to use law enforcement and the U.S. military against American citizens, she said. 
While noting that Donald Trump has repeatedly said America&#8217;s enemies are those within and not China, Russia or North Korea, Mary Trump said her uncle believes deeply that anyone who opposes him or stands up to him is his enemy and, because he is an authoritarian, by extension, the enemy of the United States. 
&#8220;My uncle sees violence committed on his behalf as the ultimate sign of love and loyalty. He wants Americans to bleed—for him,&#8221; she added. 
Did You Know?
<ul>
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Image via Shutterstock

Politics

Media

PARA

Trump's Niece Says Vance Handed Down Huge 'Advantage' In Debate With Walz, Labels Him 'Inveterate Liar'

Earnings

Reported Earlier, SunLink Health Systems Q4 EPS $0.61 Up From $(0.20) YoY, Sales $7.91M Down From $8.01M YoY

Older Model S and Model X vehicles from EV giant Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) will receive the <a href="https://www.benzinga.com/news/24/09/40681024/tesla-owners-can-now-summon-their-vehicles-using-their-phones">actually smart summon feature</a> that allows drivers to summon their vehicles in parking lots in the last quarter of 2024, company executive Ashok Elluswamy said on Monday.
What Happened: &#8220;Actually Smart Summon will come to legacy S/X in Q4,&#8221; Elluswamy wrote on social media platform X. 
Elluswamy, who is the Director of Autopilot software at Tesla, was responding to a user who flagged that though the company started rolling out the feature to newer model years of the vehicles in early September, older vehicle owners are still waiting. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Actually Smart Summon will come to legacy S/X in Q4.
&mdash; Ashok Elluswamy (@aelluswamy) <a href="https://twitter.com/aelluswamy/status/1840833897699172599?ref_src=twsrc%5Etfw">September 30, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Actually Smart Summon is the latest iteration of the smart summon feature which was removed in 2022 with the company's removal of ultrasonic sensors to rely on cameras to provide driver assistance features.
Actually Smart Summon will allow users to summon their Tesla cars to a nearby particular location and banish them once they are done using it with the Tesla app.
Tesla in September also deployed parking assistance features and its full self-driving (FSD) driver assistance software on the <a href="https://www.benzinga.com/news/24/09/41086839/tesla-cybertruck-starts-receiving-highly-anticipated-fsd-software">Cybertruck- its latest EV offering</a>. FSD, contrary to its name, does not enable autonomous driving but requires active driver supervision. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41088324/spacexs-falcon-9-rocket-grounded-3rd-time-in-3-months-launch-put-on-hold-as-company-hunts-for-root-c">SpaceX&#8217;s Falcon 9 Rocket Grounded 3rd Time In 3 Months: Launch Put On Hold As Company Hunts For &#8216;Root Cause&#8217;</a></li>
</ul>
Photo courtesy: Unsplash

Tech

TSLA

Tesla Senior Exec Says Drivers Of Older Model S, X Vehicles Can Summon Them By Last Quarter Of 2024

Equity LifeStyle Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELS#NYSE">ELS</a>) (referred to herein as the "Company," "we," "us," and "our") reported today its preliminary assessment of the impact of Hurricane Helene on its Florida, North Carolina and South Carolina properties.
No injuries to our residents, guests or employees have been reported. Certain properties were affected by flooding, wind, wind-blown debris, and falling trees and branches. We are in the process of estimating costs associated with cleanup and restoration efforts. We believe that we have adequate insurance, subject to deductibles, including business interruption coverage. At this time, we do not believe that Hurricane Helene will significantly impact our results of operations or our financial condition on a consolidated basis

Reported Earlier, Equity LifeStyle Properties Reports Minimal Impact from Hurricane Helene, Cleanup Underway

Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Cenra Healthcare, the sales and marketing arm of Cenra Inc., today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Taiwan, including Moderna's COVID-19 vaccine, Spikevax&#xAE;.
Under the agreement, Moderna will manufacture and distribute its mRNA respiratory vaccines. Cenra Healthcare will engage in promotion and execute medical education activities to ensure broad access to Moderna's mRNA respiratory portfolio across Taiwan. The agreement has an initial term until July 31, 2027, and no further details on the financial terms of the deal are being disclosed.

Government

Regulations

MRNA

Reported Earlier, Moderna and Cenra Healthcare Join Forces to Promote COVID-19 and Respiratory Vaccines in Taiwan

Over the years, billionaire investor Mark Cuban and former President Donald Trump have shared a multifaceted relationship. Their complicated and rather chaotic history started as being TV rivals.
What Happened: In 2004, Cuban&#8217;s &#8220;The Benefactor&#8221; and Trump&#8217;s &#8220;The Apprentice&#8221; began airing. While The Apprentice ran for 15 seasons, Cuban&#8217;s The Benefactor was canceled after just six episodes.
At the time, in a blog post titled &#8220;Thank you, Donald,&#8221; Cuban expressed his frustration after Trump told the Chicago Sun-Times, &#8220;You&#8217;ll have 100 people trying to do shows a little bit like us.&#8221;
&#8220;Let's get some things cleared up in case anyone is confused. The Benefactor is going to be nothing like The Apprentice. Why? Because, Donald, we are not alike in any way,&#8221; the &#8220;Shark Tank&#8221; star stated.
In the same blog post, Cuban reminisced about meeting Trump at a 1999 Super Bowl party at Mar-a-Lago, after which Trump invited him to meet in New York.
According to the billionaire, the former President&#8217;s office walls were completely covered with photos and magazine covers featuring him.
See Also: <a href="https://www.benzinga.com/general/politics/24/09/41079936/shaq-called-trump-a-straight-up-guy-before-presidency-i-think-he-just-says-it-wrong-but-did-the-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Shaq Called Trump &#8216;A Straight-Up Guy&#8217; Before Presidency, &#8216;I Think He Just Says It Wrong&#8217;</a>
&#8220;After leaving your office, I promised myself that if I ever got liquid and had an obscene amount of money in the bank, I would make a point not to remind myself and everyone else around me of it every minute of every day unlike you,&#8221; he said, adding, &#8220;I guess our definition of success is just completely different.&#8221;
Following Cuban&#8217;s blog post, Trump stated he didn&#8217;t recall meeting him. In response, Cuban wrote a follow-up post titled &#8220;Of course you don&#8217;t remember, Donald.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">A history of Donald Trump and Mark Cuban&#39;s &#39;love-hate relationship&#39; <a href="https://t.co/wDeYT6En1y">https://t.co/wDeYT6En1y</a> via <a href="https://twitter.com/BusinessInsider?ref_src=twsrc%5Etfw">@businessinsider</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1840871506835902749?ref_src=twsrc%5Etfw">September 30, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Five years later, in 2009, Cuban praised Trump for his marketing nous. &#8220;Donald&#8217;s amazing. He sets the standard for marketing and promotion and to get him involved in MMA and to partner with him is an amazing opportunity for HDNet,&#8221; he said.
Why It Matters: Despite their rivalry, Cuban initially supported Trump&#8217;s political aspirations but later became a vocal critic due to their differing views on success and the Republican nominee&#8217;s incessant self-promotion.
The duo also collaborated in 2009 to promote a mixed martial arts (MMA) event through Cuban&#8217;s HDNet network.
In 2017, Trump also retaliated against Cuban, saying the billionaire wasn&#8217;t smart enough to run for president.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I know Mark Cuban well. He backed me big-time but I wasn&#39;t interested in taking all of his calls.He&#39;s not smart enough to run for president!
&mdash; Donald J. Trump (@realDonaldTrump) <a href="https://twitter.com/realDonaldTrump/status/830769247185952772?ref_src=twsrc%5Etfw">February 12, 2017</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Last week, Cuban <a href="https://www.benzinga.com/news/24/09/41078897/billionaire-mark-cuban-admits-to-being-a-trump-supporter-in-2016-credits-long-conversation-with-form">admitted to supporting</a> Trump in 2016 but said that a conversation with his running mate JD Vance led to a change of heart.
Earlier this month, the <a href="https://www.benzinga.com/news/24/09/40849505/mark-cuban-says-he-truly-does-not-hate-trump-but-calls-him-a-lousy-president-if-he-wasnt-running">billionaire also said</a>, &#8220;I truly don't hate him [Trump] at all. I just think he was&nbsp;and would be a lousy&nbsp;president.&#8221;
In August while speaking with Vivek Ramaswamy, Cuban said, &#8220;I actually started off supporting Donald and then I got to know him better. I was like, ‘He's great, he's not a typical Stepford candidate.' I thought that was a positive, and then I got to know him.&#8221;
He added, &#8220;He was unethical then, and he&#8217;s still unethical.&#8221;
Cuban has been <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41032465/mark-cuban-is-one-of-kamala-harris-most-effective-surrogates-says-former-sc-house-rep-baka">openly supporting</a> Vice President Kamala Harris, the Democratic candidate for the 2024 presidential election.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41083520/larry-hogan-says-trump-questioning-kamala-harris-intelligence-outrageous-and-unacceptable-he-is-his?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Larry Hogan Says Trump Questioning Kamala Harris&#8217; Intelligence &#8216;Outrageous And Unacceptable&#8217;: He Is His Own &#8216;Worst Enemy&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photos courtesy: Shutterstock

Mark Cuban Once Supported Trump's Political Aspirations And Called Him 'Amazing,' But The Former TV Rivals Have Shared A Love-Hate Relationship: The 'Shark Tank' Star Made This Promise To Himself After Leaving Ex-President's Office In 2004

Li Auto Inc. ("Li Auto" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>, HKEX: 2015)))), a leader in China's new energy vehicle market, today announced that it delivered&nbsp;53,709 vehicles in September 2024, up 48.9% year over year. This brought the Company's third-quarter deliveries to 152,831, increasing by 45.4% year over year. As of September 30, 2024, Li Auto had delivered a total of&nbsp;341,812 vehicles in 2024, with cumulative deliveries reaching 975,176. &nbsp;

Reported Earlier, Li Auto Delivered 53,709 Vehicles In September, Up By 48.9% YoY

ZEEKR Intelligent Technology Holding Limited ("ZEEKR" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>), a global premium electric mobility technology company, today announced its delivery results for September 2024.
ZEEKR delivered 21,333 vehicles in September 2024, a 77% year-over-year increase. Year-to-date,&nbsp;ZEEKR has delivered 142,873 vehicles in 2024, representing 81% growth over the same period last year. As of the end of September 2024,&nbsp;ZEEKR's cumulative deliveries reached 339,506.
On September 20, 2024, ZEEKR&nbsp;officially&nbsp;unveiled its premium electric five-seater SUV, the ZEEKR 7X, with deliveries commencing the very next day. The ZEEKR 7X is designed to challenge the conventional, seamlessly combining luxurious comfort with robust off-road capabilities, making it ideal for both urban and challenging conditions.&nbsp;

Reported Earlier, Zeekr Delivered 21,333 Vehicles In September, Up By 77% YoY

Greenfire Resources Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFR#NYSE">GFR</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GFR#TSX">GFR</a>) ("Greenfire" or the "Company"), a Calgary-based energy company focused on the production and development of thermal energy resources from the Athabasca region of Alberta, Canada announces that the Alberta Securities Commission ("ASC") has set November 5, 2024 as the date for the hearing in respect of the application made by certain limited partnerships managed by Waterous Energy Fund Management Corp. (collectively, "WEF") and parties that it has entered into share purchase agreements with, namely Allard Services Limited ("Allard"), a corporation controlled by former director and Greenfire Board Chair Julian McIntyre, and Annapurna Limited ("Annapurna"), a corporation controlled by former Greenfire director Venkat Siva, and Modro Holdings LLC (together with Allard and Annapurna, the "Selling Shareholders") requesting that the ASC, among other things, cease trade the Company's shareholder protection rights plan agreement (the "Rights Plan").
Greenfire adopted the Rights Plan following the announcement on September 16, 2024 that WEF had entered into agreements with each of the Selling Shareholders to acquire 43.3% of the issued and outstanding common shares of the Company. The Company intends to defend the necessity of its Rights Plan at the ASC hearing to ensure, to the extent possible, that all shareholders of Greenfire are treated fairly and equally in connection with any unsolicited take-over bid or other attempt to acquire control of Greenfire, and to provide the Board sufficient opportunity to identify, develop and negotiate potential value-enhancing alternatives, if available, that would benefit all shareholders of the Company.
Greenfire also announces that today each of Julian McIntyre, the principal of Selling Shareholder Allard, and Venkat Siva, the principal of Selling Shareholder Annapurna, has tendered their resignation as a director of the Company.

TSX:GFR

Reported Earlier, Greenfire Faces Key Alberta Securities Commission Hearing Over Shareholder Rights Plan Amid Takeover Bid, Former Directors Resign

NASDAQ-listed <a href="https://pr.report/35db">AGAPE ATP Corporation ("ATPC")</a>, is proud to announce a strategic collaboration with <a href="https://pr.report/35dc">FORMEDIC Technologies Sdn. Bhd. ("FORMEDIC Technologies")</a> to introduce <a href="https://pr.report/35dd">LEGA</a>, an electronic chest percussion device for respiratory care. This partnership marks a major advancement in respiratory health, as the two companies combine their strengths to address the growing demand for advanced respiratory solutions.
LEGA, FORMEDIC's flagship product, assists patients with chronic obstructive pulmonary diseases ("COPD"), pneumonia, bronchiectasis, and other lung-related conditions by providing critical support for airway clearance and secretion management. LEGA helps to manage secretion drainage and airway clearance, offering much-needed relief to patients both adults and children, facing respiratory difficulties in both hospital and home care settings. This device has already gained significant traction in the medical field, with close to 2,000 units used in major hospitals and rehabilitation centres in Malaysia and globally.
For ATPC, this collaboration brings opportunities in the <a href="https://pr.report/35de">fast-growing respiratory care market, estimated to reach USD 25.95 billion in 2024, with a strong growth trajectory, estimating it to hit USD 49.84 billion by 2031</a>1. As respiratory diseases continue to rise globally, this partnership positions ATPC to capitalise on the increasing demand for advanced respiratory solutions, as well as diversifying its wellness portfolio with a proven medical device.

ATPC

Reported Earlier, AGAPE ATP and FORMEDIC Partner to Launch Advanced Respiratory Device LEGA for COPD and Lung Care

Shigeru Ishiba has been elected as Japan&#8217;s new prime minister, replacing Fumio Kishida and raising questions about future U.S.-Japan relations. 
What Happened: Experts predict how Shigeru&#8217;s appointment might crop up changes in the relations between Tokyo and Washington, as <a href="https://www.politico.com/news/magazine/2024/09/29/japans-prime-minister-ishiba-00181546">reported </a>by Politico on Monday. According to Jesper Koll, a German-born economist in Tokyo, Ishiba must overcome his reputation for micromanagement and stubbornness. Ishiba lacks a grand vision, Koll added.
For Washington, Ishiba&#8217;s stance on military relations is crucial. He has suggested revising the U.S. forces deployment agreement and amending Japan&#8217;s pacifist constitution. Ishiba also proposed an Asian NATO, potentially elevating Japan to a peer ally of the U.S.
Gerry Curtis, a retired Columbia scholar, noted that Ishiba views the current U.S. deal as outdated.
"He could be a problem for the U.S.," he said.
Ken Weinstein, a prominent Japan watcher, described Ishiba as the "hardest for Americans to read&#8221; among the other candidates.
A Japanese official explained that 60% of Ishiba&#8217;s motivation is to enhance deterrence and strengthen the alliance, while 40% is about restoring Japanese sovereignty. This dual motive makes Washington uneasy.
Ishiba stated that security issues would be discussed with the next U.S. president post-November elections. Additionally, Japan faces challenges from U.S. protectionist trade policies and restrictions on technology transfers to China, impacting Japanese manufacturers.
Hiro Akita of Nikkei described Ishiba as a realist who understands Japan must adapt to a changing world. While not seeking to push America back, Ishiba&#8217;s leadership could still stir the waters of U.S.-Japan relations.
See Also: <a href="https://www.benzinga.com/general/politics/24/09/41079936/shaq-called-trump-a-straight-up-guy-before-presidency-i-think-he-just-says-it-wrong-but-did-the-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Shaq Called Trump &#8216;A Straight-Up Guy&#8217; Before Presidency, &#8216;I Think He Just Says It Wrong&#8217; – But Did The NBA Legend Actually Vote For Trump In 2016?</a>
Despite his reputation for micromanagement, Ishiba&#8217;s election marks a shift from the policies of former Prime Minister Shinzo Abe. His pragmatic stance could bring changes to Japan&#8217;s domestic and international policies.
Why It Matters: The election of Shigeru Ishiba has already had significant economic repercussions. On Monday, Japan&#8217;s key stock market gauge<a href="https://www.benzinga.com/markets/asia/24/09/41084907/japans-nikkei-plummets-over-2-000-points-amid-change-of-guard-while-chinese-market-extends-stimulus">, the Nikkei 225</a>, plummeted over 2,000 points, or 5.02%, amid the change of leadership. The index, heavily reliant on exports, reacted negatively to Ishiba&#8217;s victory, reflecting investor uncertainty about his policies. 
Additionally, Ishiba&#8217;s stance on international trade and defense could <a href="https://www.benzinga.com/news/24/09/40745941/japan-pm-candidate-warns-bidens-opposition-to-nippons-us-steel-acquisition-could-undermine-the-trust">strain Japan&#8217;s relationship</a> with the United States. Earlier this month, Ishiba warned that President Joe Biden&#8216;s opposition to Nippon Steel&#8216;s acquisition of U.S. Steel might undermine trust between the allies. 
Did You Know?
<ul>
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Image by Sakaori via Wikimedia Commons
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Global

General

Japan's Shigeru Ishiba 'Could Be A Problem' For US, Experts Warn: 'Hardest For Americans To Read'

CPI Card Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) ("CPI" or the "Company"), a payments technology company and leading provider of credit, debit and prepaid card and digital solutions, including Software-as-a-Service (SaaS) based instant issuance, today announced the pricing of a registered underwritten secondary public offering of 1,200,000 shares of the Company's common stock to be sold by certain stockholders affiliated with Parallel49 Equity (the "selling stockholders"), at a public offering price of $21.00 per share. The underwriters were also granted a 30-day option to purchase up to an additional 180,000 shares of common stock from the selling stockholders at the public offering price, less the underwriting discount. The offering is expected to close on or about October 2, 2024, subject to the satisfaction of customary closing conditions.
The Company is not offering any shares of common stock in the offering and will not receive any proceeds from the sale of common stock by the selling stockholders. Total gross proceeds from the offering to the selling stockholders, before deducting the underwriting discount and other estimated offering expenses, are expected to be approximately $25.2 million.

Offerings

PMTS

CPI Card Group Selling Stockholders Priced $25.2M Secondary Public Offering of 1.2M Shares At $21/Share

WISeKey International Holding Ltd. ("WISeKey") ((SIX: WIHN, NASDAQ:<a href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>), a leader in cybersecurity, AI, Blockchain, and IoT operating as a holding company, today announced that will be initiating a awareness campaign to promote a major semiconductor fabrication facility (fab) project in Switzerland which marks a crucial step in the country's journey toward self-reliance in chip production and positions Switzerland as an emerging hub in the semiconductor industry.
For many years, WISeKey has been at the forefront of such efforts and has built an extensive expertise in semiconductors. Via its subsidiary. SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>), which focuses on semiconductors, PKI, and post-quantum technology products, WISeKey offers countries the opportunity to develop their own semiconductor personalization centers through Public-Private Partnerships (PPPs). This initiative aims to reduce reliance on foreign semiconductor manufacturing, thereby enhancing global supply chain security.
The development of a ab in Switzerland will require a careful balance of incentives, support, R&amp;D, innovation, and access to capital. As highly advanced facilities, semiconductor fabs face escalating costs due to various factors, and each project presents unique requirements and cost considerations. WISeKey aims to raise awareness of the essential role a Swiss-based fab will play in building the foundations for the country's innovation landscape. Given the project's complexity and cost, establishing a close partnership and a solid investment case is crucial to its success.
The project's objective in Switzerland is to start with a mini fab (a smaller-scale semiconductor fabrication facility) and gradually expand it into a full-scale semiconductor fab over the next 10 years. This phased approach allows for manageable investment, initial production capabilities, and flexibility to scale operations in line with technological advancements and market demands. Starting with a mini fab can cost between $100 million to $1.5 billion, depending on the desired technology node and production capacity. Over time, the facility can be expanded with the latest equipment and processes, eventually reaching the scale and capability of a full fab, which may involve a total investment of several billion. This gradual growth strategy aligns with Switzerland's goal of fostering a domestic semiconductor ecosystem and innovation cluster.
Currently, Switzerland heavily relies on imports to meet its semiconductor needs. This new fab project is set to mitigate that dependence, enhance the domestic chip production ecosystem, create new jobs, and attract further investments in the technology and space sector. Locally produced chips will become essential for various industries within Switzerland, contributing to a more resilient global supply chain.

LAES

WKEY

WISeKey and SEALSQ Push for Switzerland's First Semiconductor Fab to Boost Domestic Chip Production

XPeng Inc. (("XPENG" or the "Company, NYSE:<a href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), a leading Chinese smart electric vehicle ("Smart EV") company, today announced its vehicle delivery results for September and the third quarter 2024.
In September 2024, XPENG delivered 21,352 Smart EVs, a new record for monthly deliveries, representing increases of 39% year-over-year and 52% over the prior month. At the same time, the first month of deliveries of XPENG MONA M03 exceeded 10,000 units. For the first nine months of 2024, XPENG delivered 98,561 Smart EVs, a 21% increase from the same period last year.
With a broad array of superior configurations and competitive pricing, XPENG MONA M03 has experienced a significant increase in orders since its market launch. XPENG and supply chain partners are sparing no effort to prepare for XPENG MONA M03's further production ramp-up.
In September, XNGP's monthly active user penetration rate in urban driving reached 83%. XPENG rolled out its AI Tianji XOS 5.3 to all eligible owners in China on September 25, enhancing their experience with 32 feature updates and 38 functional upgrades. Empowered by end-to-end large AI models, XPENG's ADAS features can deliver seamless smart driving on all public roads, including passing electronic toll collection (ETC), navigating U-turns and roundabouts, and much more.
Additionally, after successful launch events in Madrid and Lisbon in September, XPENG officially introduced the G9, G6 and P7 models to the Spanish and Portuguese markets.
Looking ahead, the Company expects to unveil XPENG P7+, positioned as AI-defined car, in October 2024. XPENG will also showcase its state-of-the-art AI technologies and applications and its new model lineup at the 2024 Paris Motor Show from October 14 to 21.

XPEV

XPeng Reported Delivery Of 21,352 Smart EVs In September 2024, Up By 39% YoY And 52% MoM

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4267071-1&amp;h=2471754948&amp;u=http%3A%2F%2Fwww.group1corp.com%2F&amp;a=Group+1+Automotive%2C+Inc">Group 1 Automotive, Inc</a>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPI#NYSE">GPI</a>) ("Group 1" or the "Company"), a Fortune 250 automotive retailer with 260 dealerships located in the U.S. and U.K.,&nbsp;announced the appointment of Mark Raban as Chief Executive Officer ("CEO") of Group 1 Automotive U.K.
Raban brings more than 20 years of executive experience in automotive retail operations and finance to Group 1.&nbsp; In this new role, he will oversee the integration of the recently acquired Inchcape dealerships to drive strategic growth in the U.K.&nbsp; Leveraging the Company's expanded brand portfolio and presence, Raban will also focus on enhancing customer experience and reinforcing Group 1's strong OEM partnerships.
"Mark is a proven leader with a history of success in the U.K. motor trade," said Daryl Kenningham, Group 1's President and CEO.&nbsp; "Following the transformative growth of our U.K. business, he will be instrumental in creating a high-performing culture among our team members and engaging customers across our expanded dealership network."
Prior to joining Group 1, Raban progressed from Chief Financial Officer ("CFO") to CEO at Lookers Motor Group, a dealership group in the U.K. and Ireland.&nbsp; Prior to joining Lookers, he served as CFO of Marshall Motor Holdings and held senior finance roles at companies such as Inchcape Retail, Selfridges, and Borders.

Management

Group 1 Automotive Tapped Mark Raban Of Lookers Motor Group as CEO of UK Operations

Daiichi Sankyo (TSE: 4568) and AstraZeneca's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) supplemental Biologics License Application (sBLA) for ENHERTU&#xAE; (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting.
ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
The U.S. Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available treatment options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance. The Prescription Drug User Fee Act (PDUFA) date, the FDA action date for their regulatory decision, is February 1, 2025. The Priority Review follows receipt of Breakthrough Therapy Designation <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.daiichisankyo.com%2Ffiles%2Fnews%2Fpressrelease%2Fpdf%2F202408%2F20240819_E1.pdf&amp;esheet=54129231&amp;newsitemid=20240930807595&amp;lan=en-US&amp;anchor=granted&amp;index=1&amp;md5=c82129aaf52e5fdfcdcfd5c5d0f72567">granted</a> by the FDA for ENHERTU based on data from the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04494425&amp;esheet=54129231&amp;newsitemid=20240930807595&amp;lan=en-US&amp;anchor=DESTINY-Breast06&amp;index=2&amp;md5=ecfc5698cd40f1242f214ba893845e59">DESTINY-Breast06</a> phase 3 trial in August 2024.
Hormone receptor (HR) positive, HER2 negative is the most common breast cancer subtype, accounting for approximately 70% of all breast cancers.1 Despite being classified as HER2 negative, many of these tumors still carry some level of HER2 expression.2 It is estimated that up to 85% to 90% of tumors historically classified as HR positive, HER2 negative, may be HER2 low or HER2 ultralow.3,4
The sBLA is based on data from DESTINY-Breast06 <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.daiichisankyo.com%2Ffiles%2Fnews%2Fpressrelease%2Fpdf%2F202406%2F20240602_E2.pdf&amp;esheet=54129231&amp;newsitemid=20240930807595&amp;lan=en-US&amp;anchor=presented&amp;index=3&amp;md5=60d743b75d92125e38563f950191d661">presented</a> as a late-breaking oral session at the 2024 American Society of Clinical Oncology (#ASCO24) Annual Meeting and recently published in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nejm.org&amp;esheet=54129231&amp;newsitemid=20240930807595&amp;lan=en-US&amp;anchor=The+New+England+Journal+of+Medicine&amp;index=4&amp;md5=1e3a45484df713407df2ad6cdbca0eba">The New England Journal of Medicine</a>. In the overall trial population, ENHERTU reduced the risk of disease progression or death by 37% by blinded independent central review (BICR) versus chemotherapy (hazard ratio [HR] 0.63; 95% confidence interval [CI]: 0.53-0.75; p&lt;0.0001). Median progression-free survival (PFS) was 13.2 months with ENHERTU compared to 8.1 months with chemotherapy.
Results were consistent in patients with HER2 low expression and HER2 ultralow expression. In the primary endpoint analysis of patients with HR positive, HER2 low metastatic breast cancer, median PFS was 13.2 months in the ENHERTU arm compared to 8.1 months in the chemotherapy arm (HR 0.62; 95% CI: 0.51-0.74; p&lt;0.0001), as assessed by BICR. In a prespecified exploratory analysis of patients with HER2 ultralow expression, ENHERTU showed a median PFS of 13.2 months versus 8.3 months, respectively (HR 0.78; 95% CI: 0.50-1.21).
The safety profile of ENHERTU in DESTINY-Breast06 was consistent with previous breast cancer clinical trials with no new safety concerns identified. The most common grade 3 or higher treatment related treatment emergent adverse events (TEAEs) occurring in 5% or more of patients treated with ENHERTU were neutropenia (20.7%), leukopenia (6.9%) and anemia (5.8%). Interstitial lung disease (ILD) or pneumonitis occurred in 11.3% of patients treated with ENHERTU. The majority of ILD or pneumonitis events were low grade (grade 1 [n=7; 1.6%] or grade 2 [n=36; 8.3%]). There were three grade 3 ILD events (0.7%), zero grade 4 events and three grade 5 events (0.7%) as determined by an independent adjudication committee.
"This Priority Review highlights the potential to expand the existing indication of ENHERTU in HER2 low metastatic breast cancer to include use in an earlier disease setting as well as in a broader patient population that includes HER2 ultralow," said Ken Takeshita, MD, Global Head, R&amp;D, Daiichi Sankyo. "We look forward to working closely with the FDA with the goal of bringing ENHERTU to more patients as quickly as possible."
"While endocrine therapies are widely used in the initial treatment of HR positive metastatic breast cancer, most patients see limited benefit with additional lines of treatment and subsequent chemotherapy is associated with poor response rates and outcomes," said Susan Galbraith, MBBChir, PhD, Executive Vice President, Oncology R&amp;D, AstraZeneca. "The results from DESTINY-Breast06 show that ENHERTU has the potential to evolve the current HR positive treatment landscape and become the first targeted treatment for patients with HER2 low or HER2 ultralow expression following endocrine therapy."

FDA Grants Priority Review for Daiichi Sankyo and AstraZeneca's ENHERTU in Breast Cancer Treatment

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Acuity Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>) to report quarterly earnings at $4.28 per share on revenue of $1.02 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Acuity Brands shares gained 1.7% to $279.94 in after-hours trading.</li>
<li>ReposiTrak, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRAK#NYSE">TRAK</a>) reported better-than-expected fourth-quarter financial results and increased its quarterly dividend by 10%. ReposiTrak shares gained 4.6% to $19.32 in the after-hours trading session.</li>
<li>Analysts expect McCormick &amp; Company, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>) to post earnings at 67 cents per share on revenue of $1.67 million for the latest quarter. The company will release earnings before the markets open. McCormick shares gained 0.4% to $82.60 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Biohaven Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) reported a proposed $250 million public offering of common shares. Biohaven shares fell 1.9% to $49.00 in the after-hours trading session.</li>
<li>Analysts expect NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) to post quarterly earnings at 52 cents per share on revenue of $11.65 million after the closing bell. Nike shares fell 0.1% to $88.31 in after-hours trading.</li>
</ul>
Check This Out:
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41102060/jim-cramer-hand-picks-these-3-stocks-to-ride-the-crest-of-the-chinese-stimulus-frenzy">Jim Cramer Hand Picks These 3 Stocks To Ride The Crest Of The Chinese Stimulus Frenzy</a></li>
</ul>
Photo courtesy: Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

BHVN

TRAK

Acuity Brands, Nike And 3 Stocks To Watch Heading Into Tuesday

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnextracker.com%2F&amp;esheet=54129605&amp;newsitemid=20240930556809&amp;lan=en-US&amp;anchor=%3Cstrong%3ENextracker+%28Nasdaq%3A+NXT%29%2C%3C%2Fstrong%3E&amp;index=1&amp;md5=df3d8ea60b226fe827440498fc5ff3c3">Nextracker (NASDAQ:</a><a href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>),a leading global provider of intelligent solar trackers, foundations, and software solutions, today inaugurated India's first Center for Solar Excellence (CFSE) in Hyderabad, India. Spanning across 13 acres this state-of-the-art facility will serve to advance solar tracker technology, further accelerating the region's energy transition.
The CFSE will feature a 30,000 square foot, state-of-the-art lab, a comprehensive solar tracker installation, and training facilities encompassing the entire project lifecycle—from structural, mechanical, and electrical design to construction, operation, and maintenance. Working closely with supply chain partners, customers, and third-party laboratories, Nextracker's cross-functional team of experts will be developing, testing, and commercializing proprietary technologies.&nbsp;

Nextracker To Open India's First Solar Excellence Center to Boost Renewable Energy Innovation

IGM Biosciences GAAP EPS of -$0.79, revenue of $1.26M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
IGM Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/igms-stock-quote/">IGMS</a>) just reported results for the second quarter of 2024.<ul><li>IGM Biosciences reported earnings per share of -79 cents. This was below the analyst estimate for EPS of -4 cents.</li><li>The company reported revenue of $1.25 million.</li><li>This was 97.69% worse than the analyst estimate for revenue of $54.31 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/igms-stock-earnings-igm-biosciences-for-q2-of-2024/">IGMS Stock Earnings: IGM Biosciences Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

IGMS Stock Earnings: IGM Biosciences Misses EPS, Misses Revenue for Q2 2024

J.P. Morgan analyst Eric Joseph maintained a Hold rating on IGM Biosciences (IGMS – Research Report) yesterday and set a price target of $12.00. Er...

IGM Biosciences: Hold Rating with Cautious Outlook Amid Clinical Progress and Financial Losses

RBC Capital analyst Brian Abrahams maintained a Buy rating on IGM Biosciences (IGMS – Research Report) yesterday and set a price target of $20.00. ...

RBC Capital Keeps Their Buy Rating on IGM Biosciences (IGMS)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cocrystal Pharma (COCP – Research Report) and IGM Bi...

Analysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and IGM Biosciences (IGMS)

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on IGM Biosciences (IGMS – Research Report), with a ...

Truist Financial Reaffirms Their Buy Rating on IGM Biosciences (IGMS)

Analyst Robert Burns of H.C. Wainwright reiterated a Hold rating on IGM Biosciences (IGMS – Research Report), with a price target of $11.00. Robert...

IGM Biosciences: Hold Rating Affirmed Amid Financial Challenges and Clinical Catalysts

IGM Biosciences: Waiting For Godot

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on IGM Biosciences (IGMS – Research Report) and 4D Mole...

Comments

IGM Biosciences

Interés en corto

IGM Biosciences (NASDAQ:IGMS) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL